Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Oraxol vs IV Paclitaxel in Cancer Patients
NCT04035473Phase 1Completed
- Sponsor
- Athenex
- Start
- Aug 2015
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of paclitaxel + encequidar in solid tumor (2 arms), sponsored by Athenex. Primary endpoint: Area Under the Concentration-Time Curve Zero Time Extrapolated to Infinite Time. Started Aug 2015; status: completed.
02
Drugs
paclitaxel + encequidar
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04035473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04035473.